Please login to the form below

Not currently logged in
Email:
Password:

Former Astellas regulatory lead joins Oxular

Robert Waters becomes regulatory affairs VP

Oxford, UK-based retinal therapeutics specialist Oxular has appointed Robert Waters as vice president of regulatory affairs.

Waters brings over 15 years of expertise in the development and registration of products in ophthalmology to the firm, most recently as global regulatory lead for urology and ophthalmology projects at Astellas.

Prior to this, Waters served as head of European regulatory affairs development and head of emerging markets, EMEA at Allergan, having previously been its head of ophthalmology and head of regulatory development.

Tom Cavanagh, chief executive of Oxular, said: “We are delighted to welcome Robert to the Oxular team.

“Robert's deep knowledge in global regulation combined with his extensive experience in progressing ophthalmology projects to approval will be a great asset to the Company as we look to bring new ophthalmic products to market.

“As a young company, we are proud to attract somebody of Robert's calibre within the ophthalmology field and we believe that he will play a key role in helping us to achieve our goal of building a global ophthalmic franchise based on the successful development and commercialisation of our innovative and much needed treatments for retinal diseases.”

19th December 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics